Results 241 to 250 of about 81,406 (283)
Some of the next articles are maybe not open access.

Related searches:

Immunotherapy Slows TNBC Progression

Cancer Discovery, 2015
Abstract The experimental monoclonal antibody MPDL3280A extended progression-free survival and produced durable responses in some patients with triple-negative breast cancer, according to preliminary results from a phase I trial.
openaire   +1 more source

Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC

Clinical Breast Cancer, 2016
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.After obtaining institutional review ...
Tithi Biswas   +5 more
openaire   +2 more sources

ST TNBC

Data for spatial transcriptomics on triple negative breast cancers The repository contains a number of (tarballed) directories. byArray - data by array/subarray classification - data relative to the classification / regression at the spot level, as well as the per-annotation gene expressions Clinical - clinical data and link array / samples ...
openaire   +1 more source

HGH1 activation in TNBC.

We provide evidence here that a basic defining characteristic of the TNBC transcriptome in black women is high expression of the gene that encodes the human growth homolog gene, HGH1. 
openaire   +1 more source

TNBC: Immuntherapie immer bedeutsamer

gynäkologie + geburtshilfe, 2023
openaire   +1 more source

TNBC: Neues ADC punktet

InFo Hämatologie + Onkologie, 2022
openaire   +1 more source

Checkpointinhibition beim frühen TNBC

gynäkologie + geburtshilfe, 2020
openaire   +1 more source

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

Nature Reviews Clinical Oncology, 2021
Eapm Working Group For Oncology Clinical Research   +2 more
exaly  

Home - About - Disclaimer - Privacy